Nadia Agopyan - 27 Feb 2023 Form 4 Insider Report for Marker Therapeutics, Inc. (MRKR)

Reporting relationship: SVP, Regulatory Affairs
Issuer ticker: MRKR
Reported as of: 27 Feb 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Mar 2023, 15:47:45 UTC
Prior SEC filing: 22 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ Michael Loiacono, Attorney-in-Fact

Key filing fact

Nadia Agopyan filed Form 4 for Marker Therapeutics, Inc. (MRKR) on 01 Mar 2023.

Key facts

This page summarizes Nadia Agopyan's Form 4 filing for Marker Therapeutics, Inc. (MRKR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 01 Mar 2023, 15:47.

Change

Previous filing in this sequence was filed on 22 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MRKR transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +34,154
Change %
Price: $0.000000
Shares after: 34,154
Date: 27 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 34,154
Exercise price: $2.14
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option vests in equal monthly installments over a four year period commencing on March 27, 2023 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date.